App-Quantinova.ai

Increased Risk of Diabetes Mellitus in Pituitary Patients Compared to the General Population As Represented By NHANES

Alison K Cullinane - Endocrine Society (ENDO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Metabolic syndrome

Glucocorticoid

Discontinuation of Insulin, Oral Antidiabetic and Antihypertensive Medications in a Patient with Cushing-s Disease Following Mifepristone (MIFE) Therapy

Kevin C.J. Yuen - Endocrine Society (ENDO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Orthostatic hypotension

Spironolactone

Mifepristone for Refractory Cushing-s Syndrome in a Patient with CKD Hyperkalemia Undergoing Surgical Exodontia and Weight Loss: Recommendations for Clinical/Biochemical Monitoring and Perioperative Dosing

Audrey Elisabeth Arzamendi - Endocrine Society (ENDO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Addison's disease

Slow-K

High Urinary Free Cortisol and Low Insulin-like Growth Factor I Levels Are Associated with Sleep Apnea Syndrome in Non- Diabetic Men

Suelem Izumi - Endocrine Society (ENDO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Sleep apnoea

Mecasermin

Pituitary Apoplexy in an Acromegalic Pregnant Patient: An Under-Recognized Diagnosis

Gerard Daoming Lim - Endocrine Society (ENDO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Type 2 diabetes mellitus

Hydrocortisone

A Circulating Soluble (Pro)Renin Receptor Level and Its Changes with Growth Hormone Replacement in Patients with Growth Hormone Deficiency

Yasufumi Seki - Endocrine Society (ENDO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Dyslipidemia

Hydrocortisone

Epicardial Adipose Tissue Thickness in Patients with Prolactinoma

Dilek Yazici - Endocrine Society (ENDO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Vasodilation dysfunction

N/A

Serum Autotaxin Levels Correlate with Insulin Resistance and Features of the Metabolic Syndrome in Humans

Jules Aljammal - Endocrine Society (ENDO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Metabolic syndrome

N/A

A Meta-Analysis into the Effects of Leptin Replacement Therapy on Metabolic and Hepatic Endpoints of Patients with Lipodystrophy Syndromes Not Associated with the Use of HIV Protease Inhibitors

Gilberto J Paz-Filho - Endocrine Society (ENDO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Fatty Liver Disease

N/A

Dual Insulin Resistance in Muscle and Liver, but Not a Single Site, Is Associated with Visceral and Liver Lipid Accumulation in Obesity

Daniel Li Tu Chen - Endocrine Society (ENDO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Obesity

N/A

Comparison of Gut Microbiota in Obese, Diabetic and Healthy Control Individuals

Yalcin Basaran - Endocrine Society (ENDO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Type 2 diabetes mellitus

N/A

Empagliflozin (EMPA) for ?76 Weeks As Add-on to Pioglitazone with or without Metformin in Patients with Type 2 Diabetes (T2DM)

Christopher Simon Kovacs - Endocrine Society (ENDO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Urinary tract infections

metformin HCl + pioglitazone

Empagliflozin (EMPA) Monotherapy for ?76 Weeks in Drug-Nave Patients with Type 2 Diabetes (T2DM)

Michael W. Roden - Endocrine Society (ENDO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Urinary tract infections

BI-10773

Empagliflozin (EMPA) for ?76 Weeks As Add-on to Metformin in Patients with Type 2 Diabetes (T2DM)

Ludwig Merker - Endocrine Society (ENDO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Urinary tract infections

BI-10773

Growth Hormone Releasing Hormone Analogue Reduces Liver Fat in HIV-Infected Patients

Takara Leah Stanley - Endocrine Society (ENDO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Nonalcoholic fatty liver disease

hGH

Liraglutide 3.0 Mg Reduces the Prevalence of Prediabetes and Delays Onset of Type 2 Diabetes in Overweight and Obese Adults: Results from Scale Obesity and Prediabetes, a Randomized, Double-Blind and Placebo-Controlled 56-Week Trial

F Xavier Pi-Sunyer - Endocrine Society (ENDO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Type 2 diabetes mellitus

Liraglutide

Effects of Liraglutide 3.0 Mg and 1.8 Mg on Body Weight and Cardiometabolic Risk Factors in Overweight and Obese Adults with Type 2 Diabetes Mellitus (T2DM): The Scale Diabetes Randomized, Double-Blind, Placebo-Controlled, 56-Week Trial

Ralph Anthony DeFronzo - Endocrine Society (ENDO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Type 2 diabetes mellitus

Liraglutide

Novel Association Between Branched Chain Amino Acids, -Aminoisobutyric Acid and Abdominal Visceral Adiposity: A Metabolomics Study

Annemarie Rietman - Endocrine Society (ENDO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Obesity

Methadone hydrochloride

Improvement of Metabolic Syndrome (MetS) Parameters in 362 Obese Hypogonadal Men upon Long-Term Treatment with Testosterone Undecanoate (TU) Injections: Observational Data from Two Registry Studies

Ahmad Haider - Endocrine Society (ENDO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Metabolic syndrome

LPCN 1111

The Effect of Exenatide Body Weight and Glycaemic Control: It MAY be an ANTI-Obesity Drug

Mithat Bahceci - Endocrine Society (ENDO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Pancreatitis

Calcitonin

Filters

4759 Abstracts